2026-06-09 | Orviglance Data Presented Today at the Annual Radiology Congress ESGAR 2026 PDF Report Presentation Webcast
Regulatory 2026-05-04 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 4 May 2026 PDF Report Presentation Webcast
Regulatory 2026-03-30 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
2026-03-27 | ASCELIA PHARMA ANNOUNCES ACCEPTANCE OF ORVIGLANCE DATA FOR ORAL PRESENTATION AT THE ANNUAL RADIOLOGY CONGRESS ESGAR 2026 PDF Report Presentation Webcast
Regulatory 2026-01-21 | Ascelia Pharma Announces Deputy CEO Julie Waras Brogren to Leave the Company PDF Report Presentation Webcast
Regulatory 2025-12-22 | Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB PDF Report Presentation Webcast
2025-11-15 | Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review PDF Report Presentation Webcast
2025-11-10 | Ascelia Pharma Files New Patent Application for Orviglance PDF Report Presentation Webcast
Regulatory 2025-11-03 | Ascelia Pharma Announces Management Changes to Support Future Growth PDF Report Presentation Webcast
2025-09-03 | Ascelia Pharma Submits Orviglance New Drug Application to the U.S. Food and Drug Administration PDF Report Presentation Webcast
2025-08-15 | Ascelia Pharma Updates Timeline for Submission of the Orviglance NDA PDF Report Presentation Webcast
Regulatory 2025-05-07 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025 PDF Report Presentation Webcast
2025-04-08 | Ascelia Pharma Announces Publication of Orviglance Study in Investigative Radiology PDF Report Presentation Webcast
Regulatory 2025-04-04 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
2025-04-04 | Ascelia Pharma Announces Acceptance of Study on Burden of Illness Real-World Data of Orviglance Target Patients for Presentation at the ISPOR 2025 Conference PDF Report Presentation Webcast
Regulatory 2025-03-31 | The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025 PDF Report Presentation Webcast
Regulatory 2025-03-18 | Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025 PDF Report Presentation Webcast
Regulatory 2025-02-25 | Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025 PDF Report Presentation Webcast
